Assembly of mTORC3 Involves Binding of ETV7 to Two Separate Sequences in the mTOR Kinase Domain

• Published in: International journal of molecular sciences 2024-09, Vol.25 (18), p.10042
• Main Authors: Zhan, Jun, Harwood, Frank, Have, Sara Ten, Lamond, Angus, Phillips, Aaron H, Kriwacki, Richard W, Halder, Priyanka, Cardone, Monica, Grosveld, Gerard C
• Format: Article
• Language: English
• Subjects: Amino acids; Animals; Cancer; Cell Line, Tumor; Development and progression; ETV7; Experiments; Genetic aspects; Health aspects; HEK293 Cells; Humans; Kinases; Mechanistic Target of Rapamycin Complex 1 - metabolism; mTOC3; mTOR; Mutation; Phosphorylation; Physiological aspects; Protein Binding; Protein Domains; Protein kinases; Proteins; Proto-Oncogene Proteins c-ets - genetics; Proto-Oncogene Proteins c-ets - metabolism; rapamycin; Sirolimus - pharmacology; TOR Serine-Threonine Kinases - metabolism; Transcription factors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms251810042

mTOR plays a crucial role in cell growth by controlling ribosome biogenesis, metabolism, autophagy, mRNA translation, and cytoskeleton organization. It is a serine/threonine kinase that is part of two distinct extensively described protein complexes, mTORC1 and mTORC2. We have identified a rapamycin-resistant mTOR complex, called mTORC3, which is different from the canonical mTORC1 and mTORC2 complexes in that it does not contain the Raptor, Rictor, or mLST8 mTORC1/2 components. mTORC3 phosphorylates mTORC1 and mTORC2 targets and contains the ETS transcription factor ETV7, which binds to mTOR and is essential for mTORC3 assembly in the cytoplasm. Tumor cells that assemble mTORC3 have a proliferative advantage and become resistant to rapamycin, indicating that inhibiting mTORC3 may have a therapeutic impact on cancer. Here, we investigate which domains or amino acid residues of ETV7 and mTOR are involved in their mutual binding. We found that the mTOR FRB and LBE sequences in the kinase domain interact with the pointed (PNT) and ETS domains of ETV7, respectively. We also found that forced expression of the mTOR FRB domain in the mTORC3-expressing, rapamycin-resistant cell line Karpas-299 out-competes mTOR for ETV7 binding and renders these cells rapamycin-sensitive in vivo. Our data provide useful information for the development of molecules that prevent the assembly of mTORC3, which may have therapeutic value in the treatment of mTORC3-positive cancer.